IgA Nephropathy (Berger's Disease): Causes, Symptoms, Diagnosis, and Treatment
IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. It occurs when galactose‑deficient IgA1 antibodies form immune complexes that deposit in the glomerular mesangium, triggering inflammation, mesangial proliferation, and progressive scarring.
Epidemiology and Risk Factors
- Male predominance (2:1); peak onset 20–30 years.
- Higher prevalence in Asian and White populations.
- Familial clustering (~10% have affected relative); GWAS identifies loci in HLA, CFH, DEFA, TNFSF13.
- Triggers: mucosal infections (URI, GI), certain drugs (penicillins, NSAIDs), possibly gluten/alcohol.
Clinical Presentation
- Macroscopic hematuria: Cola/tea‑colored urine, often coinciding with URI (synpharyngitic).
- Microscopic hematuria + proteinuria: Incidental finding on urinalysis.
- Nephrotic syndrome: Heavy proteinuria (>3.5 g/day), edema, hypoalbuminemia (less common).
- Hypertension: Develops with declining GFR.
- Flank pain: Rare, from renal capsule stretching.
Diagnosis
- Urinalysis: Dysmorphic RBCs, RBC casts, proteinuria.
- Serology: Elevated serum IgA (50%), normal C3/C4 (excludes lupus, post‑strep). ANCA negative.
- Kidney biopsy (gold standard): Mesangial hypercellularity + IgA‑dominant immune deposits on immunofluorescence. Oxford MEST‑C score grades histologic severity (M: mesangial hypercellularity, E: endocapillary proliferation, S: segmental sclerosis, T: tubular atrophy/interstitial fibrosis, C: crescents).
Treatment
Supportive (All Patients)
- RAAS blockade: ACEi or ARB maximally tolerated to reduce proteinuria <1 g/day and slow progression. Target BP <130/80.
- SGLT2 inhibitors: Empagliflozin/dapagliflozin reduce kidney failure risk in CKD (including IgAN) with/without diabetes.
- Lifestyle: Low sodium (<2 g/day), weight control, smoking cessation, avoid NSAIDs.
Immunosuppression (High‑Risk: persistent proteinuria >1 g/day despite 3–6 mo RAASi, or active histology)
- Corticosteroids: TESTING/STOP‑IgAN regimens (6‑month tapered oral methylprednisolone/budesonide) show benefit but increase infection/metabolic risk. NefIgArd trial supports budesonide (targeted release).
- Combination: Cyclophosphamide + steroids for crescentic IgAN (rapidly progressive GN).
- Emerging: Sparsentan (endothelin/angiotensin receptor antagonist), atacicept (anti‑APRIL), narsoplimab (anti‑MASP‑2) in trials.
Prognosis
Highly variable. 30–40% reach ESKD at 20–25 years. Favorable: low proteinuria, normal GFR, minimal T/C on biopsy. Unfavorable: heavy proteinuria, hypertension, high MEST‑C score. Regular nephrology follow‑up is essential.
Kidney Disease - Related Articles
- Support Kidney Health: Natural Detox Strategies & Foods
- Kidney Function: Water Reabsorption & Fluid Balance — The Physiology of Homeostasis
- Low-Protein Diet for Kidney Health: Benefits & Guidelines
- Kidney Blood Clot: Symptoms, Risks & What to Watch For
- Vessel Due F for Kidney Health: Evaluating Ayurvedic Claims and Safety Risks
- Diabetic Kidney Failure: Symptoms, Stages & Early Detection
- Renal Reabsorption: Key Substances Returned from Filtrate to Bloodstream
